Search details
1.
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Acta Derm Venereol
; 104: adv13467, 2024 Feb 12.
Article
in English
| MEDLINE | ID: mdl-38348724
2.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10356): 908-919, 2022 09 17.
Article
in English
| MEDLINE | ID: mdl-36116481
3.
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Dermatol Ther
; 34(2): e14808, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33491259
4.
Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study.
J Am Acad Dermatol
; 83(6): 1647-1653, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-31678339
5.
Therapies for Psoriasis: Clinical and Economic Comparisons.
J Drugs Dermatol
; 19(11): 1101-1108, 2020 Nov 01.
Article
in English
| MEDLINE | ID: mdl-33196750
6.
Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol.
J Drugs Dermatol
; 19(4): 49-354, 2020 Apr 01.
Article
in English
| MEDLINE | ID: mdl-32272510
7.
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
Br J Dermatol
; 190(6): 917-919, 2024 May 17.
Article
in English
| MEDLINE | ID: mdl-38593196
8.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
J Drugs Dermatol
; 18(8): 804-813, 2019 Aug 01.
Article
in English
| MEDLINE | ID: mdl-31424712
9.
Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.
Circulation
; 136(3): 263-276, 2017 Jul 18.
Article
in English
| MEDLINE | ID: mdl-28483812
10.
GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.
Circ Res
; 119(11): 1242-1253, 2016 Nov 11.
Article
in English
| MEDLINE | ID: mdl-27654120
11.
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.
J Am Acad Dermatol
; 79(2): 345-352, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29477740
12.
Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study.
Arterioscler Thromb Vasc Biol
; 35(12): 2667-76, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26449753
13.
Eruptive collagenomas associated with adalimumab treatment of juvenile rheumatoid arthritis.
J Cutan Pathol
; 47(3): 197-201, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-32037611
14.
Dermatologic side effects of psychotropic medications.
Psychosomatics
; 55(1): 1-20, 2014.
Article
in English
| MEDLINE | ID: mdl-24099686
15.
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Dermatol Ther (Heidelb)
; 14(2): 323-339, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38340237
16.
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paediatr Drugs
; 25(1): 67-77, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36529811
17.
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
JAMA Dermatol
; 159(3): 255-266, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36723913
18.
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Dermatol Ther (Heidelb)
; 12(3): 701-714, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-35220545
19.
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Dermatol Ther (Heidelb)
; 12(12): 2797-2815, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36331713
20.
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
J Dermatolog Treat
; 33(4): 2085-2093, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-33947295